natgillin/translations-raw huggingface dataset:
The efficacy of Gilenya has been demonstrated in two studies which evaluated once-daily doses of fingolimod 0.5 mg and 1.25 mg in patients with relapsing-remitting multiple sclerosis (RRMS).
Djelotvornost Gilenye dokazana je u dva ispitivanja u kojima su se ocjenjivale doze fingolimoda od 0,5 mg i 1,25 mg jednom dnevno u bolesnika s relapsno-remitirajućom multiplom sklerozom (RRMS).
The efficacy of Harvoni (ledipasvir [LDV]/sofosbuvir [SOF]) was evaluated in three open-label Phase 3 studies with data available for a total of 1,950 patients with genotype 1 CHC.
Djelotvornost lijeka Harvoni (ledipasvir [LDV]/sofosbuvir [SOF]) bila je procijenjena u tri otvorena ispitivanja faze 3 s podacima dostupnima za ukupno 1950 pacijenata s CHC-om uzrokovanim genotipom 1.
The efficacy of hormonal contraceptives may be reduced if co-administered with olaparib (see also sections 4.4 and 4.6).
Učinkovitost hormonskih kontraceptiva može biti smanjena pri istodobnoj primjeni sa olaparibom (vidjeti i dijelove 4.4 i 4.6).
The efficacy of Humira was assessed in a randomised, double-blind, controlled study of 114 paediatric patients from 4 years of age with severe chronic plaque psoriasis (as defined by a PGA ≥ 4 or > 20% BSA involvement or > 10% BSA involvement with very thick lesions or PASI ≥ 20 or ≥ 10 with clinically relevant facial, genital, or hand/ foot involvement) who were inadequately controlled with topical therapy and heliotherapy or phototherapy.
Djelotvornost lijeka Humira ocjenjivala se u randomiziranom, dvostruko slijepom, kontroliranom ispitivanju provedenom u 114 pedijatrijskih bolesnika u dobi od 4 ili više godina s teškom kroničnom plak psorijazom (koja se definirala kao PGA rezultat od ≥ 4 ili zahvaćenost površine tijela od > 20% ili zahvaćenost površine tijela od > 10% s vrlo debelim lezijama ili PASI rezultat od ≥ 20 ili ≥ 10 uz klinički značajnu zahvaćenost lica, genitalija ili šaka/stopala) u kojih bolest nije bila dovoljno dobro kontrolirana topikalnom terapijom i helioterapijom ili fototerapijom.
The efficacy of IDELVION has been evaluated in a phase 3 study, in which a total of 27 male PTPs between 1 and 10 years (median age 6.0 years) with 12 patients < 6 years, received IDELVION for prophylaxis and control of bleeding episodes.
Djelotvornost lijeka IDELVION je ocijenjena u ispitivanju faze 3, u kojoj je ukupno 27 prethodno liječenih muških bolesnika između 1. i 10. godine (medijan dobi 6,0 godina), s 12 bolesnika <6 godina, primilo lijek IDELVION u svrhu profilakse i kontrole epizoda krvarenja.
The efficacy of Ilaris for the treatment of active SJIA was assessed in two pivotal studies (G2305 and G2301).
Djelotvornost Ilarisa u liječenju aktivne SJIA-e ocijenjena je u dva ključna ispitivanja (G2305 i G2301).
The efficacy of Ilaris for the treatment of acute gouty arthritis attacks was demonstrated in two multicentre, randomised, double-blind, active-controlled studies in patients with frequent gouty arthritis (≥ 3 attacks in the previous 12 months) unable to use NSAIDs or colchicine (due to contraindication, intolerance or lack of efficacy).
Djelotvornost Ilarisa za liječenje akutnih napada uričnog artritisa dokazana je u dva multicentrična, randomizirana, dvostruko slijepa, aktivno kontrolirana ispitivanja kod bolesnika s učestalim uričnim artritisom (≥3 napada u prethodnih 12 mjeseci) koji nisu mogli koristiti NSAIL-ove ili kolhicin (zbog kontraindikacije, intolerancije ili nedostatka djelotvornosti).
The efficacy of imiquimod 5 times per week for 6 weeks was studied in two double-blind vehicle controlled clinical trials.
Djelotvornost imikvimoda u razdoblju od jednog do 6 tjedana u dva dvostruko slijepa podlogom kontrolirana klinička ispitivanja ispitivana je primjenom imikvimoda 5 puta.
The efficacy of imiquimod applied 3 times per week for one or two courses of 4 weeks, separated by a 4 week treatment-free period, was studied in two double-blind vehicle controlled clinical trials.
Djelotvornost imikvimoda primjenjenog 3 puta tjedno, tijekom jednog ili dva ciklusa liječenja u pojedinačnom trajanju od 4 tjedna, uz 4-tjednu stanku između ciklusa liječenja proučavana je u dva dvostruko slijepa podlogom kontrolirana klinička ispitivanja.
The efficacy of infliximab through week 54 was assessed in the ACT 1 study.
Djelotvornost lijeka infliksimab tijekom 54. tjedna ispitivala se u kliničkom ispitivanju ACT 1.
The efficacy of IntronA is enhanced when given in combination with ribavirin.
Djelotvornost lijeka IntronA pojačava se kada se daje u kombinaciji s ribavirinom.
The efficacy of INVANZ in the treatment of community acquired pneumonia due to penicillin- resistant Streptococcus pneumoniae has not been established.
Nije utvrđena djelotvornost lijeka INVANZ u liječenju izvanbolnički stečene pneumonije uzrokovane bakterijom Streptococcus pneumoniae rezistentnom na penicilin.
The efficacy of ipilimumab for women above 50 years of age is therefore uncertain.
Djelotvornost ipilimumaba u žena starijih od 50 godina stoga nije sigurna.
The efficacy of JETREA was demonstrated in 2 multicentre, randomised, double-masked, placebo-controlled, 6-month studies in patients with VMT.
Djelotvornost JETREE dokazana je u dva multicentrična, randomizirana, dvostruko maskirana, placebom kontrolirana, 6-mjesečna ispitivanja u bolesnika s VMT-om.
The efficacy of Kalydeco has been evaluated in two Phase 3 randomised, double-blind, placebo-controlled, multi-centre studies of clinically stable patients with CF who had the G551D mutation in the CFTR gene on at least 1 allele and had FEV1 ≥40% predicted.
Djelotvornost lijeka Kalydeco procijenjena je u dva randomizirana, dvostruko slijepa, placebom kontrolirana, multicentrična ispitivanja faze III u klinički stabilnih bolesnika s cističnom fibrozom koji su imali mutaciju G551D gena CFTR na najmanje jednom alelu i FEV1 ≥ 40% predviđenog.
The efficacy of Kalydeco in patients less than 18 years of age with an R117H mutation in the CFTR gene has not been established.
Djelotvornost lijeka Kalydeco u bolesnika mlađih od 18 godina s mutacijom R117H gena CFTR nije ustanovljena.
The efficacy of Kineret in children with RA (JIA) aged 0 to 18 years has not been established.
Djelotvornost Kinereta u djece s RA (juvenilnim idiopatskim artritisom, JIA) u dobi od 0 do 18 godina nije ustanovljena.
The efficacy of lamivudine in patients co-infected with Delta hepatitis or hepatitis C has not been established and caution is advised.
Djelotvornost lamivudina u bolesnika koji su ujedno zaraženi hepatitisom delta (D) ili hepatitisom C nije dokazana i preporučuje se oprez.
The efficacy of lamivudine in patients co-infected with Delta hepatitis or hepatitis C has not been established and caution is advised.
Djelotvornost lamivudina u bolesnika koji su ujedno zaraženi hepatitisom delta ili hepatitisom C nije dokazana i preporučuje se oprez.
The efficacy of Leflunomide Winthrop in the treatment of rheumatoid arthritis was demonstrated in 4 controlled trials (1 in phase II and 3 in phase III).
Djelotvornost lijeka Leflunomide Winthrop u liječenju reumatoidnog artritisa pokazala se u 4 kontrolirana ispitivanja (1 u fazi II i 3 u fazi III).
The efficacy of Leflunomide Winthrop was demonstrated in one controlled, randomised, double blind study 3L01 in 188 patients with psoriatic arthritis, treated at 20 mg/day.
Djelotvornost lijeka Leflunomide Winthrop u liječenju psorijatičnog artritisa pokazala se u jednom kontroliranom, randomiziranom, dvostruko slijepom ispitivanju 3L01 na 188 bolesnika s psorijatičnim artritisom.
The efficacy of metaphylactic use of Zuprevo was demonstrated in a placebo controlled multi-centre field study, when outbreak of clinical disease was confirmed (i.e. animals in at least 30% of the pens sharing the same airspace showed clinical signs of SRD, including at least 10% animals per pen within 1 day; or 20% within 2 days or 30% within 3 days).
Učinkovitost metafilaktičke upotrebe Zupreva je dokazan uz placebo kontroliranim multi-centralnim terenskim istraživanjima, kada je klinički potvrđeno izbijanje bolesti (tj. životinje u najmanje 30% boksova, u istom zračnom prostoru su pokazale kliničke znakove DBS-a, uključujući najmanje 10% životinja po boksu, u 1 danu, ili 20% u roku od 2 dana ili 30% u roku od 3 dana).
The efficacy of oseltamivir in either treatment or prophylaxis of influenza in immunocompromised patients has not been firmly established (see section 5.1).
Djelotvornost oseltamivira u liječenju ili profilaksi gripe u imunokompromitiranih bolesnika nije sa sigurnošću utvrđena (vidjeti dio 5.1).
The efficacy of oseltamivir in preventing naturally occurring influenza illness has been demonstrated in a post-exposure prevention study in households and two seasonal prevention studies.
Djelotvornost oseltamivira u prevenciji gripe pokazana je tijekom jedne studije prevencije u kućanstvima, nakon izloženosti virusu, te u dvije sezonske studije prevencije.
The efficacy of OSSEOR was demonstrated in men with osteoporosis in a 2-year, double-blind, placebo-controlled study with a main analysis after one year in 243 patients (Intention to treat population, 161 patients received strontium ranelate) at high risk of fracture (mean age 72,7 years; mean lumbar BMD T-score value of -2.6; 28% of prevalent vertebral fracture).
Djelotvornost OSSEOR-a je dokazana kod muškaraca s osteporozom u dvogodišnjem, dvostruko- slijepom, placebom kontroliranom ispitivanju s glavnom analizom provedenom nakon jedne godine na 243 ispitanika (ITT populacija, 161 ispitanik je primao stroncijev ranelat) s visokim rizikom od prijeloma (srednja dob 72,7 godina; srednja BMD T-vrijednost za lumbalnu kralježnicu -2,6%; prevalencija prijeloma kralježnice 28%).
The efficacy of OZURDEX was assessed in two 3 year, multicentre, double-masked, randomised, sham-controlled, parallel studies of identical design which together comprised 1,048 patients (studies 206207-010 and 206207-011).
Učinkovitost lijeka OZURDEX ocjenjivana je dvama trogodišnjima, multicentričnima, dvostruko slijepima, randomiziranima, placebom kontroliranima paralelnim ispitivanjima identičnima po dizajnu, tijekom kojih je uspoređivano 1048 bolesnika (ispitivanja 206207-010 i 206207-011).
The efficacy of OZURDEX was assessed in two multicentre, double-masked, randomised, sham-controlled, parallel studies of identical design which together comprised 1,267 patients who were randomized to receive treatment with dexamethasone 350 µg or 700 µg implants or sham (studies 206207-008 and 206207-009).
Djelotvornost lijeka OZURDEX procijenjena je u dvije multicentrične, dvostruko maskirane, randomizirane, paralelne studije kontrolirane placebo postupkom, koje su bile zamišljene na identičan način i koje su zajedno obuhvatile 1267 bolesnika koji su liječeni deksametazonom u implantatima od 350 µg ili 700 µg ili placebo postupkom (studije 206207-008 i 206207-009).
The efficacy of pasireotide intramuscular use has been demonstrated in two phase III, multicentre studies.
Djelotvornost pasireotida primijenjenog intramuskularno dokazana je u dva multicentrična ispitivanja faze III.
The efficacy of Perjeta in HER2-positive breast cancer is supported by a randomised phase III comparative trial in metastatic breast cancer and two phase II studies (one single-arm trial in metastatic breast cancer and one randomised comparative trial in the neoadjuvant setting).
Djelotvornost lijeka Perjeta u HER2 pozitivnom raku dojke potvrđena je u randomiziranom komparativnom ispitivanju faze III u kojem su sudjelovali bolesnici s metastatskim rakom dojke te u dva ispitivanja faze II (jedno ispitivanje s jednom skupinom u bolesnika s metastatskim rakom dojke i jedno randomizirano komparativno ispitivanje neoadjuvantnog liječenja).
The efficacy of pramipexole (0.0625-0.5 mg/day) with paediatric patients aged 6-17 years with Tourette Disorder was evaluated in a 6-week, double-blind, randomised, placebo-controlled flexible dose study.
Djelotvornost pramipeksola (0,0625-0,5 mg/dan) ocjenjivana je na pedijatrijskim bolesnicima u dobi od 6- 17 godina s Touretteovim sindromom tijekom 6 tjedana u dvostruko-slijepom, randomiziranom, placebom kontroliranom, fleksibilnom ispitivanju doza.
The efficacy of pramipexole was evaluated in four placebo-controlled clinical trials in approximately 1,000 patients with moderate to very severe idiopathic Restless Legs Syndrome.
Djelotvornost pramipeksola bila je ocjenjivana u četiri placebom kontrolirana klinička ispitivanja na oko 1000 bolesnika s umjerenim do vrlo teškim idiopatskim sindromom nemirnih nogu.
The efficacy of Prometax transdermal patches in patients with Alzheimer’s dementia has been demonstrated in a 24-week double-blind, placebo-controlled core study and its open-label extension phase and in a 48-week double-blind comparator study.
Djelotvornost Prometax transdermalnih flastera u bolesnika s Alzheimerovom demencijom dokazana je u 24-tjednom dvostruko slijepom, placebom kontroliranom osnovnom ispitivanju i u njegovom otvorenom produžetku te u 48-tjednom dvostruko slijepom ispitivanju s komparatorom.
The efficacy of propranolol in infants (aged 5 weeks to 5 months at treatment initiation) with proliferating infantile haemangioma requiring systemic therapy has been demonstrated in a pivotal randomised, controlled, multicentre, multidose, adaptive phase II/III study aimed to compare four regimens of propranolol (1 or 3 mg/kg/day for 3 or 6 months) to placebo (double blind).
Djelotvornost propranolola kod dojenčadi (u dobi od 5 tjedana do 5 mjeseci na početku liječenja) s proliferirajućim infantilnim hemangiomom koji zahtijeva sistemsku terapiju dokazana je u ključnoj slučajno odabranoj, kontroliranoj, multicentričnoj, višedoznoj, adaptivnoj fazi II/III istraživanja čiji je cilj bio usporediti četiri režima propranolola (1 ili 3 mg/kg/dnevno tijekom 3 ili 6 mjeseci) s placebom (dvostruko slijepim).
The efficacy of PROTELOS was demonstrated in men with osteoporosis in a 2-year, double- blind,placebo-controlled study with a main analysis after one year in 243 patients (Intention to treatpopulation, 161 patients received strontium ranelate) at high risk of fracture (mean age 72,7 years; mean lumbar BMD T-score value of -2.6; 28% of prevalent vertebral fracture).
Djelotvornost PROTELOS-a je dokazana kod muškaraca s osteporozom u dvogodišnjem, dvostruko- slijepom, placebom kontroliranom ispitivanju s glavnom analizom provedenom nakon jedne godine na 243 ispitanika (ITT populacija, 161 ispitanik je primao stroncijev ranelat) s visokim rizikom od prijeloma (srednja dob 72,7 godina; srednja BMD T-vrijednost za lumbalnu kralježnicu -2,6%; prevalencija prijeloma kralježnice 28%).
The efficacy of qHPV vaccine against the combined incidence of HPV 16- or 18-related persistent infection, genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was 84.7% (95% CI: 67.5, 93.7).
Djelotvornost cjepiva qHPV protiv kombinirane incidencije perzistentne infekcije, genitalnih bradavica, vulvarnih i vaginalnih lezija, CIN-a bilo kojeg stupnja, AIS-a i raka cerviksa povezane s tipovima 16 ili 18 HPV-a iznosila je 84,7% (95% CI: 67,5; 93,7).
The efficacy of qHPV vaccine in 24- through 45-year-old women was assessed in 1 placebo- controlled, double-blind, randomized Phase III clinical study (Protocol 019, FUTURE III) including a total of 3,817 women.
Djelotvornost cjepiva qHPV u žena u dobi od 24 do 45 godina bila je ocijenjena u 1 placebom kontroliranom, dvostruko slijepom, randomiziranom kliničkom ispitivanju faze III (Protokol 019, FUTURE III) koje je uključilo ukupno 3817 žena.
The efficacy of rasagiline was established in three studies: as monotherapy treatment in study I and as adjunct therapy to levodopa in the studies II and III.
Djelotvornost razagilina je utvrđena u tri ispitivanja: kao monoterapija u ispitivanju I i kao dodatna terapija levodopi u ispitivanjima II i III.
The efficacy of repeated infusions with infliximab in patients with fistulising Crohn’s disease was studied in a 1-year clinical study (ACCENT II).
Djelotvornost ponovljenih infuzija infliksimaba u bolesnika s fistulirajućim oblikom Crohnove bolesti ispitivala se u jednogodišnjem kliničkom ispitivanju (ACCENT II).
The efficacy of reslizumab in eosinophilic asthma (blood eosinophils ≥400 µL-1) was evaluated in three randomised, double-blind, placebo-controlled studies (Studies I to III) from 16 to 52 weeks’ duration involving 1268 patients with moderate to severe asthma inadequately controlled on medium- to high-dose inhaled corticosteroids (ICS) (at least 440 μg of fluticasone propionate daily or equivalent) with or without other controllers; prior stable allergen immunotherapy was allowed.
Djelotvornost reslizumaba kod eozinofilne astme (eozinofili u krvi ≥400 µl-1) bila je procijenjena u tri randomizirana, dvostruko slijepa, placebom kontrolirana ispitivanja (Ispitivanja I do III) u trajanju od 16 do 52 tjedna, koja su uključila 1268 bolesnika s umjerenom do teškom astmom koja nije bila odgovarajuće kontrolirana pomoću srednjih do visokih doza inhalacijskih kortikosteroida (najmanje 440 µg flutikazon propionata dnevno ili istovrijedno tome) uz primjenu drugih lijekova za kontrolu astme ili bez njih; bila je dopuštena prethodna stabilna alergenska imunoterapija.
The efficacy of Resolor was established in three multicentre, randomised, double-blind, 12-week placebo-controlled studies in subjects with chronic constipation (n=1,279 onResolor, 1,124 females, 155 males).
Djelotvornost lijeka Resolor ustanovljena je u tri multicentrična, randomizirana, dvostruko slijepa, placebom kontrolirana ispitivanja u trajanju od 12 tjedana u ispitanika s kroničnom konstipacijom (lijek Resolor je primalo n = 1279; 1124 žena i 155 muškaraca).
The efficacy of REYATAZ/ritonavir in combination with tenofovir disoproxil fumarate in treatment- experienced patients has been demonstrated in clinical study 045 and in treatment naive patients in clinical study 138 (see sections 4.8 and 5.1).
Djelotvornost lijeka REYATAZ s ritonavirom u kombinaciji s tenofovirdizoproksilfumaratom u prethodno liječenih bolesnika dokazana je u kliničkom ispitivanju 045, a u bolesnika koji prethodno nisu bili liječeni u kliničkom ispitivanju 138 (vidjeti dijelove 4.8 i 5.1).
The efficacy of rilpivirine is based on the analyses of 96 weeks data from two randomised, double-blind, controlled studies in treatment-naïve patients (TMC278-C209 and emtricitabine+tenofovir disoproxil fumarate subset of TMC278-C215).
Djelotvornost rilpivirina utemeljena je na analizi podataka iz 96 tjedana u dva randomizirana, dvostruko slijepa, kontrolirana ispitivanja bolesnika koji prethodno nisu bili liječeni (TMC278-C209 i podskupini u TMC278-C215 s emtricitabinom+tenofovirdizoproksilfumaratom).
The efficacy of rivastigmine has been established through the use of three independent, domain specific, assessment tools which were assessed at periodic intervals during 6 month treatment periods.
Djelotvornost rivastigmina utvrđena je korištenjem tri neovisne, područno specifične ljestvice za procjenu, koje su upotrebljavane u periodičkim intervalima tijekom razdoblja liječenja od 6 mjeseci.
The efficacy of rivastigmine in dementia associated with Parkinson’s disease has been demonstrated in a 24-week multicentre, double-blind, placebo-controlled core study and its 24-week open-label extension phase.
Djelotvornost rivastigmina kod demencije povezane s Parkinsonovom bolešću demonstrirana je u 24-tjednom multicentričnom, dvostruko slijepom, placebo kontroliranom, osnovnom ispitivanju te njegovoj 24-tjednoj otvorenoj produženoj fazi.
The efficacy of rivastigmine in dementia associated with Parkinson’s disease has been demonstrated in a 24-week multicentre, double-blind, placebo-controlled core study and its 24-week open-label extension phase.
Djelotvornost rivastigmina kod demencije povezane s Parkinsonovom bolešću pokazana je u 24- tjednom multicentričnom, dvostruko slijepom, placebo kontroliranom, osnovnom ispitivanju te njegovoj 24-tjednoj otvorenoj produženoj fazi.
The efficacy of rivastigmine in dementia associated with Parkinson’s disease has been demonstrated in a 24-week multicentre, double-blind, placebo-controlled core study and its 24-week open-label extension phase.
Djelotvornost rivastigmina u demenciji povezanoj s Parkinsonovom bolešću pokazana je u 24-tjednom multicentričnom, dvostruko slijepom, placebo kontroliranom, osnovnom ispitivanju te njegovoj 24- tjednoj otvorenoj produženoj fazi.
The efficacy of rivastigmine in dementia associated with Parkinson’s disease has been demonstrated in a 24-week multicentre, double-blind, placebo-controlled core study and its 24-week open-label extension phase.
Djelotvornost rivastigmina u demenciji povezanoj s Parkinsonovom bolešću pokazana je u 24-tjednom multicentričnom, dvostruko slijepom, placebo kontroliranom, osnovnom ispitivanju, te njegovoj 24- tjednoj otvorenoj produženoj fazi.
The efficacy of rivastigmine transdermal patches in patients with Alzheimer’s dementia has been demonstrated in a 24-week double-blind, placebo-controlled core study and its open-label extension phase and in a 48-week double-blind comparator study.
Djelotvornost transdermalnih flastera s rivastigminom u bolesnika s Alzheimerovom demencijom dokazana je u 24-tjednom dvostruko slijepom, placebom kontroliranom osnovnom ispitivanju i u njegovom otvorenom produžetku te u 48-tjednom dvostruko slijepom ispitivanju s komparatorom.
The efficacy of selexipag on the primary endpoint was consistent across subgroups of age, sex, race, aetiology, geographical region, WHO FC, and as monotherapy or in combination with an ERA or a PDE-5 inhibitor or triple combination with both an ERA and a PDE-5 inhibitor.
Djelotvornost seleksipaga u pogledu primarne ciljne točke bila je dosljedna u svim podskupinama s obzirom na dob, spol, rasu, etiologiju, geografsko područje, WHO FC stupanj te na primjenu u monoterapiji ili u kombinaciji s ERA-om ili inhibitorom PDE-5 ili u trostrukoj kombinaciji s ERA-om i inhibitorom PDE-5.
The efficacy of Selincro in reducing alcohol consumption in patients with alcohol dependence (DSM-
Djelotvornost Selincra u smanjenju konzumacije alkohola u bolesnika s ovisnošću o alkoholu (DSM
The efficacy of Selincro was also evaluated in a randomised, double-blind, parallel-group, placebo-controlled 1-year study.
Djelotvornost Selincra bila je također procijenjena u randomiziranom, dvostruko slijepom, placebom kontroliranom jednogodišnjem ispitivanju paralelnih skupina.
The efficacy of sildenafil in patients already on bosentan therapy has not been conclusively demonstrated (see sections 4.5 and 5.1).
Djelotvornost sildenafila u bolesnika već liječenih bosentanom još nije sa sigurnošću dokazana (vidjeti dio 4.5 i 5.1).
The efficacy of Silgard against the combined incidence of HPV 16- or 18-related persistent infection, genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was 41.6% (95% CI: 24.3, 55.2).
Djelotvornost cjepiva Silgard s obzirom na kombiniranu incidenciju perzistentne infekcije, genitalnih bradavica, vulvarnih i vaginalnih lezija, CIN-a bilo kojeg stupnja, AIS-a i karcinoma vrata maternice povezanih s HPV-om 16 ili 18 iznosila je 41,6% (95% CI: 24,3; 55,2).
The efficacy of Silgard against the combined incidence of HPV 16- or 18-related persistent infection, genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was 84.7% (95% CI: 67.5, 93.7).
Djelotvornost cjepiva Silgard s obzirom na kombiniranu incidenciju perzistentne infekcije, genitalnih bradavica, vulvarnih i vaginalnih lezija, CIN-a bilo kojeg stupnja, AIS-a i karcinoma vrata maternice povezanih s tipovima HPV-a 16 ili 18 iznosila je 84,7% (95% CI: 67,5; 93,7).
The efficacy of Silgard against the combined incidence of HPV 6-, 11-, 16-, or 18-related persistent infection, genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was 47.2% (95% CI: 33.5, 58.2).
Djelotvornost cjepiva Silgard obzirom na kombiniranu incidenciju perzistentne infekcije, genitalnih bradavica, vulvarnih i vaginalnih lezija, CIN-a bilo kojeg stupnja, AIS-a i karcinoma vrata maternice povezanih s HPV-om 6, 11, 16 ili 18 iznosila je 47,2% (95% CI: 33,5; 58,2).